Azenta, Inc. (NASDAQ:AZTA – Get Free Report) has been given an average recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $41.20.
A number of equities analysts have recently weighed in on AZTA shares. Needham & Company LLC upped their price target on shares of Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings downgraded shares of Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th.
Check Out Our Latest Stock Analysis on Azenta
Institutional Inflows and Outflows
Azenta Price Performance
Shares of NASDAQ AZTA opened at $37.40 on Monday. The stock has a fifty day moving average price of $27.92 and a 200 day moving average price of $25.06. Azenta has a 1-year low of $15.93 and a 1-year high of $41.73. The company has a market cap of $1.64 billion, a PE ratio of -13.55 and a beta of 1.36.
Azenta (NASDAQ:AZTA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%. The firm had revenue of $161.18 million during the quarter, compared to analysts’ expectations of $149.31 million.
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
See Also
- Five stocks we like better than Azenta
- Deere Earnings: Has the Stock Outrun the Farm Cycle?
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
